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Invariant natural killer T cells (iNKT cells) are CD1d-restricted, lipid antigen-reactive T lym-
phocytes with immunoregulatory functions. iNKT cell development in the thymus proceeds
through subsequent stages, defined by the expression of CD44 and NK1.1, and is dic-
tated by a unique gene expression program, including microRNAs. Here, we investigated
whether miR-155, a microRNA involved in differentiation of most hematopoietic cells,
played any role in iNKT cell development.To this end, we assessed the expression of miR-
155 along iNKT cell maturation in the thymus, and studied the effects of miR-155 on iNKT
cell development using Lck-miR-155 transgenic mice, which over express miR-155 in T cell
lineage under the lymphocyte-specific protein tyrosine kinase (Lck) promoter. We show
that miR-155 is expressed by newly selected immature wild-type iNKT cells and turned
off along iNKT cells differentiation. In transgenic mice, miR-155 over-expression resulted
in a substantial block of iNKT cell maturation at Stage 2, in the thymus toward an over-
all reduction of peripheral iNKT cells, unlike mainstream T cells. Furthermore, the effects
of miR-155 over-expression on iNKT cell differentiation were cell autonomous. Finally, we
identified Ets1 and ITK transcripts as relevant targets of miR-155 in iNKT cell differentia-
tion. Altogether, these results demonstrate that a tight control of miR-155 expression is
required for the development of iNKT cells.
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INTRODUCTION
Invariant natural killer T (iNKT cells) cells are a unique T cell lin-
eage characterized by the expression of a conserved semi-invariant
αβ TCR, NK receptors, and by innate effector properties (1).
NKT semi-invariant TCR is composed of an invariant α chain
(Vα24Jα18 in human beings and Vα14Jα18 in mice), which cou-
ples with a limited repertoire of TCR β chains (preferentially
Vβ11 in humans and Vβ2, Vβ7, and Vβ8.2 in mouse) (1). The
semi-invariant TCR recognizes both self and bacterial glycolipid
ligands presented by the antigen-presenting molecule CD1d (2),
as well as at least one endogenous peptide involved in multiple
disease conditions (3). This wide recognition confers iNKT cells
the ability to act as regulators of immune homeostasis (4), as well
as sentinels to invading pathogens. Accordingly, iNKT cells play
important functions in autoimmune diseases, cancer, infection,
and inflammation.
As conventional T lymphocytes, iNKT cells are generated in the
thymus from CD4+CD8+ double positive (DP) precursors, upon
stochastic rearrangement of the invariant TCR and positive selec-
tion by CD1d-expressing DP thymocytes (5, 6). Positively selected
iNKT cells follow a defined developmental program, involv-
ing three subsequent stages defined by the expression of CD44
and NK1.1 and the down-regulation of the heat stable antigen
(HSA or CD24). In particular, Stage 1 (CD24loCD44loNK1.1−)
iNKT cells proliferate extensively to expand their pool; Stage
2 (CD24loCD44hiNK1.1−) iNKT cells become effector-memory
cells; Stage 3 (CD24loCD44hiNK1.1+) iNKT cells up-regulate NK
cell receptors such as NK1.1 and become terminally differenti-
ated thymic residents (7, 8). Many factors have been described as
crucial for this maturation path, including transcription factors
(such as c-Myc, Egr2, Ets1, PLZF, T-bet), signal transducers (such
as ITK and Irf1), and other molecules (as WASp and Osteopontin)
[reviewed in Ref. (9)]. Emigration of iNKT cells from the thy-
mus occurs mostly at Stage 2 through the lymphotoxin-β and the
sphingosine 1-phosphate receptors. The peripheral acquisition of
NK markers by iNKT cells is gained via CD1d-dependent mecha-
nisms, but the complete functional maturation requires a final step
in which the correct levels of SHP-1 phosphatase in iNKT cells are
tuned by CD1d-expressing DCs (10).
MicroRNAs are small endogenous RNAs that play important
gene-regulatory roles by pairing to the mRNAs of protein-coding
genes to direct their posttranscriptional repression (11). Despite
their relatively recent identification, growing evidence indicates
that microRNAs are crucial controllers of the programs directing
cell differentiation in the immune system, as demonstrated in mice
mutants for Dicer, the RNase III enzyme that generates functional
microRNAs. In particular, conditional deletion of Dicer causes
significant impairment in the generation of functional regulatory
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T cell subsets, such as FoxP3+ regulatory T (Treg) cells (12) and
iNKT cells (13). The search for the relevant individual microRNA
involved in Treg development and function identified micro-
RNA155 (miR-155) as a key factor for Treg maintenance. miR-155
is processed by Dicer from BIC, a non-coding transcript highly
expressed in B and T cells and in monocytes/macrophages. In Treg,
miR-155 is directly regulated by FoxP3 and targets suppressor of
cytokine signaling 1 (SOCS1), leading to increased sensitivity of
IL-2R to IL-2 (14, 15).
On the iNKT cell side, two groups identified miR-150 as the
essential microRNA for thymic and peripheral iNKT cell matu-
ration (16, 17). Notably, Zheng et al. described a partial block in
thymic and peripheral iNKT maturation in miR-150 KO mice,
whereas Lanier’s group showed a substantial reduction of iNKT
cells in mice over-expressing miR-150. These data suggest that a
dynamic and tightly regulated expression of miR-150 is required
for optimal iNKT cell development.
Beyond the above-described role in Treg function, miR-155 has
gained attention for its role in cancer. A moderate increase of miR-
155 levels has been observed in many types of malignancies of B
cell or myeloid origin, and some of us have shown that transgenic
over-expression of miR-155 in mice results in cancer (18).
Given the relevance of miR-155 for the homeostasis of the
immune system, in this study, we investigated the role of miR-
155 in iNKT cells. Surprisingly, we found that miR-155 over-
expression deeply impacts iNKT cell development, a result that
stresses the importance of tight regulation of miRNAs for their
correct functioning.
MATERIALS AND METHODS
MICE
C57BL/6 wild-type (wt) mice were purchased from Charles River
(Italy). Mice were maintained under pathogen-free conditions
at the animal facility of Fondazione IRCCS “Istituto Nazionale
dei Tumori”. Animal experiments were authorized by the Insti-
tute Ethical Committee and performed in accordance to institu-
tional guidelines and national law (DL116/92). Lck-miR-155 tg
mice were generated as previously described (19) and were pro-
vided by Dr. Carlo Maria Croce (Wexner Medical Center and
Comprehensive Cancer Center, The Ohio State University).
CELL PREPARATIONS, ANTIBODIES, FLOW CYTOMETRY, AND CELL
SORTING
Single-cell suspensions from thymus, liver, spleen, and bone
marrow (BM) were prepared as previously described (6).
PerCPCy5.5 anti-HSA (M1/69), APC anti-TCRβ (H57-597),
PE-Cy7 anti-NK1.1 (PK136), FITC anti-CD44 (IM7), FITC anti-
CD45.1 (A20), PE-Cy7 anti-CD4 (GK1.5), and APC anti-CD8
(53-6.7) were purchased from eBioscience. PBS-57-loaded CD1d-
tetramers were kindly provided by NIH Tetramer Core Facility at
Emory University (task order # 14724). Surface staining was per-
formed by incubating antibodies and tetramers at 5µg/ml on ice
for 30 min in PBS containing 2% FBS. Flow cytometry data were
acquired on a LSR Fortessa (Becton Dickinson) and analyzed with
FlowJo software (version 8.8.7; Treestar Inc.).
Invariant natural killer T cells pooled from thymocytes from wt
and Lck-miR-155 tg mice were sorted using a FACSaria (Becton
Dickinson) as:
HSA−TCRβ+tetramer+CD44loNK1.1− Stage 1 cells,
HSA−TCRβ+tetramer+CD44hiNK1.1− Stage 2 cells,
HSA−TCRβ+tetramer+CD44hiNK1.1+ Stage 3 cells.
Purity after sorting assessed around 98%.
REAL TIME RT-PCR
Fifty nanograms of total RNA, isolated by using the miRNeasy
miRNA isolation kit (Qiagen), were subjected to reverse tran-
scription according to the manufacturer’s instructions (Applied
Biosystems). Quantitative Real time RT-PCR analysis for miR-
155 (assay ID: 002571) was performed according to the TaqMan
MicroRNA Assays (Applied Biosystems) and samples normalized
by evaluating RNA U6 (assay ID: 001973) expression.
RNA was extracted according to the manufacturer’s
instructions (RNeasy MICROKIT, Qiagen) and reverse tran-
scribed using High-Capacity® cDNA Reverse Transcription Kits
(Applied Biosystem). Real time RT-PCR were performed on
7900 HT (Applied Biosystem), using TaqMan® Fast Univer-
sal PCR masterMix (Applied Biosystem). Assays (Ets1 assay
ID: Mm01175819_m1; Itk assay ID: Mm00439862_m1) and
samples were normalized by evaluating HPRT1 (assay ID:
Mm01545399_m1) expression. Results were obtained using the
comparative Ct method.
BM TRANSPLANTATION
Bone marrow cells were obtained by flushing the cavity of femurs
from donor mice. Cells from Lck-miR-155 tg mice were mixed
at 1:1 ratio with CD45.2 wt cells. Lck-miR-155 recipient mice
were lethally γ irradiated with 1000 cGy (given as a split dose
500+ 500 cGy with a 3-h interval). Two hours later, mice were
injected i.v. with 107 mixed BM cells. Recipient mice received
0.4 mg/ml gentalyn in the drinking water starting 1 week before
irradiation and maintained thereafter.
LUCIFERASE ASSAY
The 3′-UTRs of human ITK and ETS1 cloned downstream of
Renilla luciferase gene were purchased from Switchgear Genomics
and used according to the manufacturer’s instructions. Renilla
luciferase assays were performed in MEG-01 cells 48 h after trans-
fection (n= 10). The miR-155 target sites present on ITK-3′-UTR
and ETS1-3′-UTR target site 1 and target site 2 (underlined)
were mutated as indicated below (underlined and bold) using
the shown corresponding primers. The mutations were prepared
using QuikChange II XL Site-Directed Mutagenesis Kit from Agi-
lent following manufacturer’s protocol. Sequencing of the clones
was done to confirm the presence of each mutation. For ETS1, the
double mutant clone (ETS-1-M1, 2) was prepared on the clone
were the first miR-155 target site was previously mutated.
ITK original sequence:
GGATATGTCCTCATTCCATAGAGCATTAGAAGCTGCCAC
CAGCCCAGG
ITK mutated sequence (M):
GGATATGTCCTCATTCCATAGAGCGGTAGAAGCTGCCAC
CAGCCCAGG
Primers used for mutation:
ITKS 5′-GTCCTCATTCCATAGAGCGGTAGAAGCTGCCAC
CAG
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ITKAS 5′-CTGGTGGCAGCTTCTACCGCTCTATGGAATGAG
GAC
ETS original target site 1:
GGACTTAATGTTGAGCTAAGAAGCATTAAGTCTTTGAAC
TGAATGTATTTTGCATCCC
ETS mutated target site 1 (M1):
GGACTTAATGTTGAGCTAAGAAGCGGTAAGTCTTTGAAC
TGAATGTATTTTGCATCCC
Primers used for mutation:
ETS1S
5′-GGACTTAATGTTGAGCTAAGAAGCGGTAAGTCTTTGA
ACTGAATG
ETS1AS
5′-CATTCAGTTCAAAGACTTACCGCTTCTTAGCTCAACA
TTAAGTCC
ETS original target site 2:
GGAGATGAACACTCTGGGTTTTACAGCATTAACCTGCCT
AACCTTCATGGTG
ETS mutated target site 2 (M2):
GGAGATGAACACTCTGGGTTTTACAGCGGTAACCTGCCT
AACCTTCATGGTG
Primers used for mutation of target site 2 (M2):
ETS2S 5′-GAACACTCTGGGTTTTACAGCGGTAACCTGCC
TAACC
ETS2AS 5′-GGTTAGGCAGGTTACCGCTGTAAAACCCAGA
GTGTTC
The miR-Control and miR-155 were purchased from Life Tech-
nologies (catalog number AM17110 and PM12601, respectively).
The miR-Control molecule is a random sequence, which has been
extensively tested in human cell lines and tissues and has no known
target transcripts. The miR-Control was used as a baseline for
evaluating the effects of miR-155 on Est1 and Itk transcripts.
STATISTICAL ANALYSIS
The graphs and the analysis of data were performed using Prism
software (GraphPad Software, Inc.). Results are expressed as
means± SEM or SD. Statistical analysis was performed using
a two-tailed Student’s t -test with confidence intervals of 95%.
Data were considered significantly different at p< 0.05 (*p< 0.05,
**p< 0.01, ***p< 0.005 by Student’s t -test).
RESULTS
miR-155 IS DOWN-MODULATED ALONG THYMIC iNKT CELL
MATURATION
To evaluate the expression of miR-155 in thymic iNKT cells at
different stages of maturation, we sorted Stage 1, Stage 2, and
Stage 3 iNKT cells from 8 weeks old wild-type (wt) C57BL/6 mice,
according to PBS-57-loaded CD1d-tetramers, TCRβ, NK1.1, and
CD44 staining. Consistently with published literature, Stage 2 and
3 accounted for the majority of iNKT cells at this age, with Stage 1
representing <10% of HSA-negative iNKT cells (Figure 1A). The
relative expression of miR-155 (compared to endogenous control
small nuclear RNA U6) was higher in Stage 1, and decreased pro-
gressively in Stage 2 and Stage 3 iNKT cells (Figure 1B, white
bars). These data indicated that miR-155 is down-modulated
along iNKT cell maturation, suggesting that miR-155 may be
important for early events in iNKT cell lineage instruction, but
FIGURE 1 |miR-155 expression in Stage 1, 2, and 3 wt and Lck-miR-155
tg iNKT cells. (A) Representative plots of the sorting strategy employed to
sort wt and miR-155 tg thymic iNKT cells. iNKT cells were identified as
HSA−TCRβ+CD1d-tetramer+ thymocytes, and sorted as Stage 1
(CD44−NK1.1−), Stage 2 (CD44+NK1.1−), and Stage 3 (CD44+NK1.1+) cells.
(B) Evaluation of miR-155 levels in sorted cells, as assessed by RT-PCR.
White bars represent wt iNKT cells, gray bars represent Lck-miR-155 tg
iNKT cells. The graph shows the pooled results of two independent
experiments (in which six mice per group were combined).
becomes irrelevant or even detrimental for further maturation.
In conventional T cells, miR-155 is expressed at higher levels by
CD4+ and CD8+ single positive (SP) cells than by CD4−CD8−
double negative (DN) and CD4+CD8+ DP thymocytes (Figure
S1A in Supplementary Material) and (20), indicating a different
regulation exerted on and by miR-155 in iNKT and T cell subsets.
To assess whether the regulation of miR-155 along iNKT cell
maturation in the thymus is relevant for the development of
these cells, we analyzed the effects of a sustained and promi-
nent expression of miR-155 on iNKT cells development, taking
advantage from the Lck-miR-155 transgenic (tg) mice (19). These
mice express miR-155 at high levels in T lymphocytes beginning at
the DN stage (Figure S1B in Supplementary Material), including
iNKT cells. Compared to their wt counterparts, Stage 1 iNKT cells
from Lck-miR-155 tg mice expressed sevenfold more miR-155,
and expression was maintained at the same levels in Stage 2 and
3 (Figure 1B, gray bars). Lck-miR-155 tg mice thus represent the
ideal model to study the significance of miR-155 down-regulation
in iNKT cell development.
THYMIC AND PERIPHERAL iNKT CELL MATURATION IS IMPAIRED IN
Lck-miR-155 MICE
We then assessed miR-155 involvement in iNKT cell development
by comparing thymus and peripheral organs of 8 weeks old wt
and Lck-miR-155 tg mice, in terms of iNKT cell frequency, num-
bers, and phenotype. Interestingly, tg thymi were normal in total
cell numbers (Figure 2A), but displayed alterations in the relative
distribution of thymocytes in the DN, DP, and SP compartments
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(not shown), reasonably caused by miR-155 deregulation in devel-
oping tg thymocytes. Thymi from tg mice contained significantly
more iNKT cells than wt mice (75± 32× 104 cells in tg versus
55± 14× 104 cells in wt mice, p= 0.033) (Figures 2B,C), but the
great majority of the tg iNKT pool was constituted by cells with an
immature phenotype. In fact, whereas wt iNKT cells were mostly
Stage 3 NK1.1+ cells, tg iNKT cells encompassed mostly Stage 2
NK1.1− cells (Figures 2D,E), with only few mature NK1.1+ cells.
In contrast to the higher number of thymic iNKT cells, found
in tg mice, peripheral iNKT cells were reduced in all the com-
partments analyzed, i.e., liver, spleen, and BM (Figures 3A–C),
especially if analysis was restricted to mature NK1.1+ cells, in
comparison to the wt counterparts.
These results indicate that miR-155 over-expression in T cells
arrests iNKT cell maturation at Stage 2 in the thymus and in the
peripheral compartments, which results in an overall reduction
of iNKT cells in periphery. Therefore, miR-155 critically regulates
iNKT cell differentiation program.
DEFECTIVE MATURATION OF THYMIC NKT CELLS FROM Lck-miR-155 tg
MICE IS CELL INTRINSIC
To dissect the mechanisms by which miR-155 over-expression
impairs iNKT cell differentiation, we first ruled out that miR-
155 over-expression might somehow affect thymic expression
of CD1d, the major presenting molecule involved in iNKT cell
generation. As shown in Figure 4A, DP, CD4+, and DN thymo-
cytes from Lck-miR-155 tg and wt mice expressed similar levels
of CD1d. CD8+ thymocytes from Lck-miR-155 tg mice displayed
instead significantly lower levels of CD1d compared to the wt
counterpart. As iNKT cells are positively selected by DP thy-
mocytes and no existing data prove a relevant role for CD8+
thymocytes in the selection and maturation of iNKT cells, we have
reasons to believe that iNKT cell generation is not affected by
impaired CD1d expression in CD8+ thymocytes in Lck-miR-155
tg mice.
To determine whether the iNKT cell developmental defect
caused by miR-155 over-expression is instead cell autonomous,
we verified whether the development of miR-155 over-expressing
iNKT cells could be rescued by wt thymocytes in mixed BM
chimeras. Lethally irradiated Lck-miR-155 tg mice were recon-
stituted with an equal mixture of BM cells derived from CD45.1
wt mice and CD45.2 Lck-miR-155 tg mice. As shown in Figure 4B,
in the thymi of the BM chimeras the majority of iNKT cells derived
from the CD45.1 wt BM were mature NK1.1+ cells. In contrast,
iNKT cells derived from the CD45.2 Lck-miR-155 BM cells mostly
displayed an immature NK1.1- phenotype.
Finally, we ruled out that iNKT cells from Lck-miR-155 tg mice
might be characterized by altered homeostasis, impairing their
differentiation program in the thymus. As determined by BrdU
incorporation in vivo, miR-155 over-expression did not modify
FIGURE 2 | iNKT cells from Lck-miR-155 tg thymi display an immature
phenotype. (A)Total cell number of thymi isolated from wt (white bar) and
Lck-miR-155 tg mice (gray bar). (B) Percentage and (C) absolute number of
iNKT cells in the thymi of wt (white bar) and Lck-miR-155 tg mice (gray bar).
(D) Representative plots of thymic iNKT cells from wt and tg mice. iNKT cells
were identified as HSA−TCRβ+CD1d-tetramer+ thymocytes, and then
analyzed for CD44 and NK1.1 expression. (E) Bars showing the relative
distribution in Stage 1, 2, and 3 of wt and miR-155 tg iNKT cells. White color
represents Stage 1, light gray represents Stage 2 and dark gray represents
Stage 3 iNKT cells. One representative of three independent experiments
with five mice per group. Data are presented as mean±SEM. *p<0.05,
***p< 0.005, two-tailed Student’s t -test.
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FIGURE 3 | iNKT cells are reduced in peripheral organs of
Lck-miR-155 tg mice. Representative stainings and histograms
summarizing iNKT cell frequency, absolute number, and NK1.1+
expression in liver (A), spleen (B) and bone marrow (C) of wt and
Lck-miR-155 tg mice. iNKT cells were identified as
TCRβ+CD1d-tetramer+ cells. One representative of three independent
experiments with five mice per group. Data are presented as
mean±SEM. *p<0.05, ***p<0.005, two-tailed Student’s t -test.
the proliferation of thymic iNKT cell in comparison with the wt
counterpart (Figure S2 in Supplementary Material).
Thus, impaired iNKT cell maturation caused by miR-155 over-
expression could not be rescued by wt thymocytes; in addition,
iNKT cells derived from wt BM developed correctly in the thymic
stroma of Lck-miR-155 tg mice. Collectively, these results indicate
a cell-autonomous role for miR-155 in the control of iNKT cell
differentiation.
Lck-miR-155 tg iNKT CELLS FAIL TO UP-REGULATE Ets1 AND Itk UPON
MATURATION
The search for the potential miR-155 targets in iNKT cells identi-
fied Ets1 and Itk (inducible T cell kinase) molecules as the most
likely candidates. Ets1 is a member of the Ets winged helix-turn-
helix transcription factor family. Itk belongs to the Tec family of
non-receptor tyrosine kinases, which plays a significant role in sig-
naling downstream of the TCR. Although in different cell types,
both Ets1 (21) and Itk (22) have been shown to represent direct
targets of miR-155 regulation. Both Ets1 KO (23, 24) and Itk KO
(25) mice display a severe impairment in iNKT cells, characterized
by an arrest at Stage 2 that closely resembles the condition of Lck-
miR-155 tg mice. Considering the relevance of both Ets1 and Itk in
iNKT differentiation and the regulatory roles exerted by miR-155
on these two genes, we investigated them further.
We determined the expression of Ets1 and Itk transcripts in
Stage 1, 2, and 3, iNKT cells isolated from wt and Lck-miR-
155 tg mice. As shown in Figure 5, wt iNKT cells up-regulate
both transcripts upon maturation from Stage 1 to 2 and 3: in
particular, Ets1 increases up to 13-fold from Stage 1 to Stage 3,
whereas Itk has a 5-fold induction. In contrast, in iNKT cells from
Lck-miR-155 tg mice, Stage 1 cells have a four to sixfold higher
expression of both transcripts compared to the wt counterparts,
but their expression decreases upon maturation, resulting in a
severe reduction of Ets1 and Itk expression in Stage 3 cell com-
pared to wt cells. The defective down-modulation of Ets1 and Itk
at the Stage 1 and 2 of miR-155 tg iNKT cells might be due to
the presence of a shorter isoform of their 3′UTR that may occur
during differentiation/maturation (26).
In the wt setting, Ets1 and Itk up-regulation along
iNKT cell thymic maturation is paralleled by a concomitant
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FIGURE 4 | miR-155 over-expression intrinsically affects iNKT cell
maturation in Lck-miR-155 tg mice. (A) Representative plot of thymic
populations according to CD4 and CD8 expression, and CD1d expression
on DP, CD4 SP, CD8 SP, and DN cells isolated form the thymus of wt
(black line) and miR-155 tg (gray filled) mice. (B) Experimental scheme of
mixed BM chimera generation. Eight weeks after transplantation, thymi
were collected and frequency and maturation stage of wt (CD45.1) and
miR-155 tg (CD45.2) NKT cells were evaluated. Plots are representative
of one mouse of five. Data are presented as mean±SEM. ***p<0.005,
two-tailed Student’s t -test. DP, double positive; CD4 SP, CD4 single
positive; CD8 SP, CD8 single positive; DN, double negative; BM, bone
marrow.
decrease in miR-155 levels (Figure 1B); in tg iNKT cells, which
over-express miR-155 (Figure 1B), expression of Ets1 and Itk
is instead consistently down-modulated at least in Stage 3.
These results strongly suggest the existence of a regulatory
function exerted by miR-155 over Ets1 and Itk in iNKT cell
maturation.
Ets1 AND Itk ARE DIRECT miR-155 TARGETS IN iNKT CELLS
Function and immune response activities of miR-155 are con-
served in both mouse and human (27). To further validate that
miR-155 modulates iNKT cell maturation through the target-
ing of Ets1 and Itk transcripts, the 3′UTRs of Ets1 and Itk were
cloned downstream of Renilla luciferase gene and the effects of
miR-155 were assayed on luciferase reporter assays. Cotransfec-
tion of the wt constructs, or either Luciferase-Ets1-3′UTR or
Luciferase-Itk-3′UTR, with miR-155 resulted in the reduction of
the luciferase activity compared to the effects of miR-control.
miR-155 over-expression also significantly reduced the expres-
sion of Luciferase-Ets1-3′UTR-M1 and Luciferase-Ets1-3′UTR-
M2 constructs, each containing a single mutated miR-155 site,
suggesting that each of the miR-155 target site in the Ets1 clone
is functional. These effects were abolished when both putative
miR-155 target seed sites were mutated on the Luciferase-Ets1-
3′UTR (Figure 6A). Mutation of miR-155 target site on the Itk
transcript also impaired the miR-155 downregulating effects on
the Luciferase-Itk-3′UTR expression (Figure 6B). Altogether, these
data demonstrate that miR-155 directly targets Ets1 and Itk tran-
scripts, and further establish miR-155 as a key regulator of iNTK
differentiation.
DISCUSSION
Invariant natural killer T cells are unconventional T cells, and,
as such, follow a unique differentiation program. Upon positive
selection by CD1d expressed on immature DP thymocytes, iNKT
maturtion passes through three developmental stages according to
CD44 and NK1.1 expression. This maturation process is strictly
controlled by transcription factors, signals transduced (9), and
microRNA (13).
Our study reveals for the first time a novel mechanism of
control in iNKT cell maturation process, which involves the phys-
iological decrease of miR-155, such to ensure the up-regulation
of its targets (Itk and Ets1), and therefore proper iNKT lympho-
cyte maturation. We show that abundant and sustained expres-
sion of miR-155 in immature and mature T cells results in
a dramatic defect in late-stage maturation of iNKT cells, and
accordingly reduced number of iNKT cells in the peripheral
compartments. Our data integrate previous studies on the con-
trol of iNKT cell physiology by microRNAs, and indicate that a
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FIGURE 5 | iNKT cells over-expressing miR-155 fail to up-regulate Ets1
and Itk upon maturation. (A) Ets1 and (B) Itk transcripts expression level
was evaluated in sorted Stage 1, 2, and 3 iNKT cells isolated from wt (white
bars) and Lck-miR-155 tg (gray bars) mice. Along wt iNKT development
both Ets1 and Itk are up modulated, mirroring the down-modulation of
miR-155. On the contrary in miR-155 tg iNKT, the expression of both
transcripts is impaired. Data are representative of two independent
experiments, each counting five mice for group.
complex and coordinated interaction with different microRNAs
and their target is likely involved in the pathway of iNKT cell
differentiation.
The crucial role exerted by miR-155 in regulating lymphocyte
biology was demonstrated in a B cell restricted miR-155 transgenic
mouse model. In these mice, the over-expression of miR-155 under
the Eµ promoter caused uncontrolled pre-B cell proliferation
followed by high-grade lymphoma/leukemia (18).
Interestingly, despite the dramatic consequences of miR-155
over-expression in B cells, none of the Lck-miR-155 tg mice under
our observation developed thymomas or peripheral malignan-
cies, suggesting that miR-155 regulates different targets in B and
T lymphocytes, and that the targets in T cells might not necessary
be tumor suppressor genes. It is also highly probable that the lev-
els of miR-155 transgene expression under the Lck promoter did
not reach the high levels reached by Eµ promoter in B cells. As
the effects of the microRNAs are often dose dependent this might
explain the lack of leukemogenesis in Lck-miR-155 tg mice.
Although the over-expression of miR-155 in Lck-miR-155 mice
does not cause a neoplastic transformation, several studies high-
lighted the importance of a regulated expression of this microRNA
in both CD4+ and CD8+ T lymphocytes (28). In particular, it was
demonstrated that in CD4+Foxp3+ regulatory T cells, miR-155
regulate SOCS1, intervening in the loop that, starting from FoxP3
and through SOCS1, leads to a sustained IL-2R signaling, necessary
for Treg homeostasis (14).
FIGURE 6 | Ets1 and Itk are direct targets ofmiR-155. MEG-01 cells were
co-transfected with luciferase reporter constructs containing either the
wild-type or the mutated (A) ETS1-, and (B) ITK1-3′UTRs and with either
miR-155 or miR-Control (ctr) and assessed for luciferase activity (RLU) 48 h
after the transfection (n=10).
In light of these observations, we extended the study of miR-
155 to iNKT lymphocytes. We identified two targets of miR-155
in iNKT cells: Ets1 and Itk. Several studies have contributed to
demonstrate that numerous molecules downstream the TCR are
key for the development of iNKT cells, which strongly relies on the
strength of TCR signaling in response to cognate interaction with
CD1d. ITK is a member of the Tec family of non-receptor protein
tyrosine kinases, which includes Rlk and Tec, and is important for
effective signaling through the TCR. In the absence of ITK, iNKT
cells are reduced in the thymus and periphery, and in both com-
partments they show a defective NK1.1 up-regulation, indicative
of a failure to progress to Stage 3 (29). Defective ITK expression
has been linked to an impaired induction of the transcription fac-
tor T-bet, the master regulator of iNKT cell maturation (30). Our
data from Lck-miR-155 tg mice phenocopy those obtained in Itk
KO mice, and show opposite expression levels of miR-155 and ITK
in developing iNKT cells. Moreover, in both Itk KO and Lck-miR-
155 tg mice, CD8 SP cells display reduced CD1d expression; this
finding has probably no functional meaning, but constitutes an
additional indication of the actual interaction between miR-155
and Itk in thymocytes. Similarly, Ets1 was also linked to the T cell
maturation, via controlling the expression of TCRα gene (31).
We propose that miR-155 acts in itself as a modulator of TCR
strength signaling by modulating the levels of Itk and Ets1 and
consequently modulating iNTK cell maturation.
In conclusion, our study supports a novel regulatory role for
miR-155 in the unique developmental program of iNKT cells and
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suggests that a dynamic regulation of miR-155 levels is critical for
the physiology of these immunoregulatory cells.
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